The EPTRI survey to map expertise and experience on units working in paediatric research in Europe, is approaching to its end.
From April 2018, more than 240 units from 26 countries answered to the survey in one or more fields. In details, 82 units (33.8%) described their expertise in Human Development and Paediatric Medicines Discovery (pluripotent stem cell, 3D cell cultures, target validation, patient derived cell assays, micro-fluidics, high-throughput cell image analysis, etc), while 73 units (30.1%) declared to perform biomarkers identification/validation in paediatric diseases and 16 of them host biobanks exsclusively dedicated to paediatric samples.
Concerning the field of Developmental Pharmacology, 52 units (21.4%) declared to provide services such as microdosing, analytical methods adapted to low sample volumes, PBPK, pop-PK and PK/PD, modelling PK, and facilities such as placental platform for drug evaluation. Finally, also in the area of Paediatric Medicines Formulations and Medical Devices, 35 units (14.4%) reported their expertise in preformulative paediatric science and 12 units (5%) declared to have expertise in paediatric medical devices. Available data demonstrate that the technical platforms proposed in EPTRI represent a large scientific community including competences, services, innovative technologies and tools.
The survey, developed within WP3, has been reopened in January 2019, with specific questionnaires targeted on the areas of expertise of the 4 platforms (Human Development and Paediatric Medicines Discovery, Paediatric Biomarkers and Biosamples; Developmental Pharmacology; Paediatric Medicines Formulations and Medical Devices). The survey will remain open for completion up to the end of April. Then, received answers will be globally analysed.
If you are willing to participate you can contact [email protected] or you can click on one of the following links and you will be redirected to the survey questionnaires: